LONHALA MAGNAIR KIT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LONHALA MAGNAIR KIT (LONHALA MAGNAIR KIT).
Glycopyrrolate is a long-acting muscarinic antagonist (LAMA) that inhibits acetylcholine at M3 receptors in bronchial smooth muscle, leading to bronchodilation.
| Metabolism | Primarily hydrolyzed by esterases and minimally metabolized by CYP enzymes (CYP2D6 and CYP3A4). |
| Excretion | Primarily hepatic metabolism; renal excretion of unchanged drug accounts for approximately 20% of the dose. Fecal elimination accounts for the remainder as metabolites. |
| Half-life | Terminal elimination half-life is approximately 6-7 hours after inhalation, supporting twice-daily dosing. |
| Protein binding | 82-88% bound to human plasma proteins, primarily to albumin. |
| Volume of Distribution | Volume of distribution is approximately 0.3-0.5 L/kg, indicating distribution into extracellular fluid. |
| Bioavailability | Absolute bioavailability after oral inhalation is approximately 30% of the delivered dose due to high first-pass metabolism. |
| Onset of Action | Bronchodilation begins within 5 minutes after inhalation, with peak effect at 1-2 hours. |
| Duration of Action | Duration of bronchodilation is approximately 12 hours, consistent with twice-daily dosing regimen. |
| Molecular Weight | 236.3 |
1 inhalation (25 mcg glycopyrrolate) twice daily via the Magnair device.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for GFR ≥30 mL/min; not recommended for GFR <30 mL/min due to lack of data. |
| Liver impairment | No dose adjustment required for Child-Pugh A or B; not studied in Child-Pugh C. |
| Pediatric use | Not approved for pediatric patients <18 years of age. |
| Geriatric use | No specific dose adjustment; monitor for anticholinergic effects in elderly patients, especially those with cognitive impairment or glaucoma. |
| 1st trimester | Insufficient human data; animal studies show no risks. Use only if benefit outweighs potential risk. |
| 2nd trimester | Insufficient human data; animal studies show no risks. Use only if benefit outweighs potential risk. |
| 3rd trimester | Insufficient human data; animal studies show no risks. Use only if benefit outweighs potential risk. |
Clinical note
Comprehensive clinical and safety monograph for LONHALA MAGNAIR KIT (LONHALA MAGNAIR KIT).
| Placental transfer | Based on molecular weight, expected to cross placenta; no specific human data. |
| Breastfeeding | No human data available; excreted in milk in animal studies. Use with caution, considering importance to mother. |
| Lactation Rating |
■ FDA Black Box Warning
Not for acute episodes of bronchospasm or for the treatment of asthma. Paradoxical bronchospasm may occur.
| Serious Effects |
Hypersensitivity to glycopyrrolate or any component of the formulation
| Precautions | Paradoxical bronchospasm may occur, Immediate hypersensitivity reactions, Worsening of narrow-angle glaucoma, Worsening of urinary retention, Use with caution in patients with severe renal impairment (CrCl <30 mL/min) |
| Food/Dietary | No specific food interactions known. However, avoid grapefruit juice if taking concurrent medications that are CYP3A4 substrates (not directly applicable to glycopyrrolate as it is not extensively metabolized by CYP enzymes). In general, maintain adequate hydration to reduce potential anticholinergic side effects such as dry mouth and constipation. |
Loading safety data…
| L3 (Moderately Safe) |
| Teratogenic Risk | LONHALA MAGNAIR KIT (glycopyrrolate) inhalation solution is an anticholinergic. Limited human data; in animal studies, no evidence of harm at clinically relevant exposures. Risk cannot be ruled out; use only if clearly needed. First trimester: insufficient data but anticholinergics generally not major teratogens. Second and third trimesters: may cause decreased fetal heart rate variability and fetal tachycardia; avoid near term due to potential risk of neonatal anticholinergic effects. |
| Fetal Monitoring | Monitor lung function and respiratory status. In pregnancy, consider fetal monitoring (e.g., ultrasound for growth, nonstress test) due to potential fetal effects from maternal hypoxia. No specific fetal monitoring required solely for glycopyrrolate, but general prenatal care with attention to fetal heart rate and growth if used chronically. |
| Fertility Effects | No human studies on fertility. In animal studies, no adverse effects on fertility at exposure levels similar to clinical use. Potential anticholinergic effects on cervical mucus or uterine motility are theoretical; unlikely to impact fertility at inhalation doses. |
| Clinical Pearls | LONHALA MAGNAIR KIT (glycopyrrolate) is a long-acting muscarinic antagonist (LAMA) administered via oral inhalation using the Magnair device. Monitor for paradoxical bronchospasm, immediate hypersensitivity reactions, and urinary retention in patients with prostatic hyperplasia or bladder neck obstruction. Not indicated for acute bronchospasm; use a rescue inhaler for acute symptoms. Avoid contact with eyes; may cause mydriasis if sprayed into eyes. Assess inhaler technique regularly to ensure proper dosing. |
| Patient Advice | Use exactly as prescribed; do not use for sudden breathing problems. · Prime the Magnair device before first use by releasing 3 test sprays into the air. · Breathe in slowly and deeply through the mouthpiece; hold breath for 5-10 seconds after each inhalation. · Rinse mouth with water after each use to reduce the risk of thrush. · Keep away from eyes; if accidental contact occurs, rinse with water for several minutes. · Store at room temperature (20-25°C); do not freeze or expose to heat. · Do not stop taking this medication without consulting your doctor. |